Know Cancer

or
forgot password

Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy


Phase 4
18 Years
N/A
Not Enrolling
Both
Arrhythmia, Respiratory Arrest

Thank you

Trial Information

Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy


Inclusion Criteria:



- Patients with hepatoma scheduled for treatment with percutaneous ethanol instillation

Exclusion Criteria:

- contraindication for the administration of atropine like

- narrow angle glaucoma

- mechanic stenoses of the GI-tract

- clinically relevant prostatic hypertrophy

- paralytic ileus

- myasthenia gravis

- severe cerebral sclerosis

- acute lung edema

- acute myocardial infarction

- cardiac insufficiency

- hyperthyroidism

- patients with contraindication to undergo percutaneous ethanol instillation

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Occurrence of dysrhythmias

Outcome Time Frame:

during percutaneous ethanol instillation

Safety Issue:

Yes

Principal Investigator

Arnulf Ferlitsch, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical University of Vienna

Authority:

Austria: Ethikkommission

Study ID:

atropinePEI

NCT ID:

NCT00575523

Start Date:

October 2003

Completion Date:

January 2008

Related Keywords:

  • Arrhythmia
  • Respiratory Arrest
  • atropine
  • percutaneous ethanol instillation
  • hepatoma
  • bradycardia
  • arrhythmia
  • Apnea
  • Arrhythmias, Cardiac
  • Liver Neoplasms
  • Carcinoma, Hepatocellular

Name

Location